Zealand Pharma to host conference call on November 11 at 4:00 p.m. CET (10:00 a.m.ET) to present third quarter results for 2021

0

Company announcement – n ° 64 / 2021

Zealand Pharma Host a conference call on November 11 at 4:00 p.m. CET (10:00 a.m.ET) to present third quarter results for 2021

Copenhagen, DK and Boston, MA, United States November 4, 2021 – Zealand Pharma A / S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based drugs, today announced that it will host a conference call on November 11 2021 at 4:00 p.m. CET (10 a.m.ET) following the announcement of third quarter 2021 results.

President and CEO Emmanuel Dulac, Zealand Pharma US President Frank Sanders, Senior Vice President and CFO Matt Dallas and Executive Vice President and Medical Director Adam Steensberg will be present at the call. The presentation will be followed by a question-and-answer session. The conference call will be conducted in English and the call numbers are as follows:

Denmark, toll free ……………………………………… 80 711,246
Denmark, Copenhagen …………………………… +45 32 720 417
UK……………………………………….. … +44 (0) 844 481 9752
United States………………………………………… . +1 646 741 3167
France paris……………………………………….. ………………. … +33 (0) 170700781
Netherlands, Amsterdam …………………… +31 (0) 207956614
International…………………………………………. .. + 44 (0) 2071 928338
Confirmation code: ………………………….. 9606399

A live audio webcast of the call, including a slide presentation, will be available through the following link, https://edge.media-server.com/mmc/p/9zezcohh, and will be accessible in the Investors section of Zealand’s website (www.zealandpharma.com/investor). Due to the increased demand for conference calling services, it may take longer to connect to the call. Participants are advised to register for the webcast 30 minutes before the scheduled start, if possible. A recording of the event and a transcript will be available in the Investors section of Zealand’s website after the call.

# # #

About Zealand Pharma A / S
Zealand Pharma A / S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of peptide-based drugs. More than 10 drug candidates invented by Zealand have advanced in clinical development, of which two have reached the market and three are at advanced stages of development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in patients with diabetes. pediatric patients and adults with diabetes aged 6 years and over. To support these two commercialized products, Zealand has built a dedicated sales force in the United States and established itself as a fully integrated biotechnology company. Additionally, licensed collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from the Zeeland-invented experimental peptide agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has a presence in the United States, including key locations in Boston and Marlborough (MA). For more information on Zeeland business and activities, please visit http://www.zealandpharma.com.

V-go® and Zegalogue® are registered trademarks of Zealand Pharma A / S.

Forward-looking statement
The above information contains forward-looking statements which provide Zealand Pharma’s expectations or forecasts regarding future events. These forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from the expectations set forth herein and may cause some or all of these forward-looking statements to be inaccurate. If any or all of these forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All of these forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this press release.

For more information, please contact:

Main logo


Source link

Share.

Comments are closed.